SCHEMBL25535499

SCHEMBL25535499

c1ccc(-c2cc(-c3ccccc3-c3ccccc3)nc(-c3ccc(-c4cccc5c4-c4ccccc4C5(c4ccccc4)c4ccccc4)c4ccccc34)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
AGTR1 P30556 2/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 8/20 0.33
KMT2A Q03164 8/20 0.33
LMNA P02545 4/20 0.33
TDP1 Q9NUW8 2/20 0.33
MAPK10 P53779 1/20 0.33
ALDH1A1 P00352 5/20 0.33
HPGD P15428 5/20 0.33
KDM4E B2RXH2 4/20 0.33
ACACA Q13085 1/20 0.32
NTSR1 P30989 1/20 0.31
ADORA1 P30542 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25535492 0.95 MEN1 (0.35) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535505 0.93 MEN1 (0.35) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535264 0.92 MEN1 (0.36) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535496 0.92 MEN1 (0.36) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535267 0.92 MAOB (0.33) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL22058947 0.92 MAPT (0.37) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535537 0.91 ENPP1 (0.38) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535536 0.91 MEN1 (0.36) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535503 0.91 MEN1 (0.35) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL25535254 0.91 MEN1 (0.38) MAPTSMN1; SMN2CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE PIEZO1, LEF1, L1CAM MAPT 1595/4885SMN1; SMN2 2672/4885CYP1A2 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.